These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 26882814)

  • 1. Association of Genetic Polymorphisms in UDP-Glucuronosyltransferases 2B17 with the Risk of Pancreatic Cancer in Chinese Han Population.
    Che X; Yu D; Wu Z; Zhang J; Chen Y; Han Y; Wang C; Qi J
    Clin Lab; 2015; 61(12):1905-10. PubMed ID: 26882814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The UGT2B17 gene deletion is not associated with prostate cancer risk.
    Olsson M; Lindström S; Häggkvist B; Adami HO; Bälter K; Stattin P; Ask B; Rane A; Ekström L; Grönberg H
    Prostate; 2008 Apr; 68(5):571-5. PubMed ID: 18247404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UDP-glucuronosyltransferase 2B17 genotyping in Japanese athletes and evaluation of the current sports drug testing for detecting testosterone misuse.
    Okano M; Ueda T; Nishitani Y; Kano H; Ikekita A; Kageyama S
    Drug Test Anal; 2013 Mar; 5(3):166-81. PubMed ID: 22887913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.
    Cai L; Huang W; Chou KC
    Protein Pept Lett; 2012 Jan; 19(1):62-9. PubMed ID: 21919858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.
    Eskandari-Nasab E; Hashemi M; Rezaei H; Fazaeli A; Mashhadi MA; Moghaddam SS; Arbabi F; Jahantigh M; Taheri M
    Mol Biol Rep; 2012 Dec; 39(12):10531-9. PubMed ID: 23053953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.
    Park J; Chen L; Ratnashinge L; Sellers TA; Tanner JP; Lee JH; Dossett N; Lang N; Kadlubar FF; Ambrosone CB; Zachariah B; Heysek RV; Patterson S; Pow-Sang J
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1473-8. PubMed ID: 16896035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys.
    Juul A; Sørensen K; Aksglaede L; Garn I; Rajpert-De Meyts E; Hullstein I; Hemmersbach P; Ottesen AM
    J Clin Endocrinol Metab; 2009 Mar; 94(3):1005-11. PubMed ID: 19088161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians.
    Gallagher CJ; Kadlubar FF; Muscat JE; Ambrosone CB; Lang NP; Lazarus P
    Cancer Detect Prev; 2007; 31(4):310-5. PubMed ID: 17935910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer.
    Gallagher CJ; Muscat JE; Hicks AN; Zheng Y; Dyer AM; Chase GA; Richie J; Lazarus P
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):823-8. PubMed ID: 17416778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk.
    Angstadt AY; Berg A; Zhu J; Miller P; Hartman TJ; Lesko SM; Muscat JE; Lazarus P; Gallagher CJ
    Cancer; 2013 Jul; 119(13):2477-85. PubMed ID: 23575887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional variants in cell death pathway genes and risk of pancreatic cancer.
    Yang M; Sun T; Wang L; Yu D; Zhang X; Miao X; Liu J; Zhao D; Li H; Tan W; Lin D
    Clin Cancer Res; 2008 May; 14(10):3230-6. PubMed ID: 18483392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UDP-glucuronosyltransferase 2B17 genotype and the risk of lung cancer among Austrian Caucasians.
    Gruber M; Le T; Filipits M; Gsur A; Mannhalter C; Jäger U; Vanura K
    Cancer Epidemiol; 2013 Oct; 37(5):625-8. PubMed ID: 23850147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
    Habibi M; Mirfakhraie R; Khani M; Rakhshan A; Azargashb E; Pouresmaeili F
    Gene; 2017 Nov; 634():47-52. PubMed ID: 28882566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation.
    Schulze JJ; Lundmark J; Garle M; Skilving I; Ekström L; Rane A
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2500-6. PubMed ID: 18334593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate.
    Karypidis AH; Olsson M; Andersson SO; Rane A; Ekström L
    Pharmacogenomics J; 2008 Apr; 8(2):147-51. PubMed ID: 17387331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests.
    Schulze JJ; Lundmark J; Garle M; Ekström L; Sottas PE; Rane A
    Steroids; 2009 Mar; 74(3):365-8. PubMed ID: 19056415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue distribution and relative gene expression of UDP-glucuronosyltransferases (2B7, 2B15, 2B17) in the human fetus.
    Ekström L; Johansson M; Rane A
    Drug Metab Dispos; 2013 Feb; 41(2):291-5. PubMed ID: 23223495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between functional promoter -94 ins/del ATTG polymorphism in NF-κ B1 gene and the risk of urinary cancer.
    Li X; Gao Y; Zhou H; Xu W; Li P; Zhou J; Xu T; Yu B; Xu Z; Zou Q; Yin C; Cai H; Shen W
    Cancer Biomark; 2016; 16(1):11-7. PubMed ID: 26484607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.
    Park JY; Tanner JP; Sellers TA; Huang Y; Stevens CK; Dossett N; Shankar RA; Zachariah B; Heysek R; Pow-Sang J
    Urology; 2007 Aug; 70(2):374-9. PubMed ID: 17826523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males.
    Zhu AZ; Cox LS; Ahluwalia JS; Renner CC; Hatsukami DK; Benowitz NL; Tyndale RF
    Pharmacogenet Genomics; 2015 May; 25(5):263-9. PubMed ID: 25794161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.